Tilray
 | |
| Public | |
| Traded as | NASDAQ: TLRY |
| Industry | Pharmaceutical, cannabis |
| Founded | 2013 |
| Headquarters | Nanaimo, Canada |
| Website |
www |
Tilray is a Canadian pharmaceutical and cannabis company headquartered in Nanaimo, British Columbia. The company received extensive coverage when its stock rose dramatically on 19 September 2018.[1][2][3]
History
Tilray was founded in 2013. It was incorporated under the umbrella of Seattle-based Privateer Holdings. Tilray became the first medical cannabis producer in North America to be GMP certified in December 2016. In July 2018 the company became the first Cannabis company to IPO on the NASDAQ.[4]
Current board members
- Brendan Kennedy (2018) – Tilray CEO
- Christine St.Clare (2018) – Ret. Partner, KPMG
- Rebekah Dopp (2018) – Principal, Google
- Scotty Greenwood (2018) – Principal, Dentons
- Michael Auerbach (2018) – Senior Vice President, Albright Stonebridge Group
References
- ↑ Speights, Keith (2018-09-19). "It's Time for a Reality Check About Tilray -- The Motley Fool". The Motley Fool. Retrieved 2018-09-19.
- ↑ "Tilray shows the highs, lows of investing in pot". Retrieved 2018-09-19.
- ↑ "How the Canadian cannabis company Tilray became worth more than American Airlines". Vox. Retrieved 2018-09-19.
- ↑ "Public shareholders got high today on Tilray, the first marijuana company to IPO on Nasdaq". TechCrunch. Retrieved 2018-09-20.
- ↑ https://www.tilray.com/boardofdirectors
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.